Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Abstract Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of either E39 or E39′ (an attenuated version of E39) to...

Full description

Bibliographic Details
Main Authors: Tommy A. Brown, Kevin Byrd, Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, Diane F. Hale, Garth S. Herbert, John W. Myers, Julia M. Greene, John S. Berry, Jonathan Martin, John C. Elkas, Thomas P. Conrads, Kathleen M. Darcy, Chad A. Hamilton, George L. Maxwel, George E. Peoples
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Cancer Medicine
Subjects:
E39
endometrial cancer
FBP
immunotherapy
ovarian cancer
vaccine
Online Access:https://doi.org/10.1002/cam4.2378

Internet

https://doi.org/10.1002/cam4.2378

Similar Items